November 25, 2016

Home 2

AngioSoma Inc.

PUBLICLY-TRADED, CLINICAL STAGE BIOTECHNOLOGY COMPANY

Ticker: SOAN

Audio interview with David P. Summers Ph.D.
Released on October 25, 2016, Uptick Newswire’s Jasyn Blair interviewes David Summers, Ph.D.

Latest Event November 2016 Shareholder Presentation. View in:  PDF | PPT

AngioSoma Inc.
Ticker: SOAN
Status: Fully Reporting
SEC Reporting: Current
Latest Filing: 10Q

Business Description

AngioSoma, Inc., a Nevada corporation, is a clinical stage biotechnology company focused on improving the effectiveness of current standard-of-care treatments, especially related to endovascular interventions in the treatment of peripheral artery disease (PAD). The Company is developing its lead product, a drug candidate called LiprostinTM for the treatment of peripheral artery disease, or PAD, which has completed FDA Phase I and three Phase II clinical trials. We are in discussions with several contract research organizations for completion of our FDA protocol for Phase III and submission of our new drug application for marketing in the US and its territories.

Authorized Shares: 480,000,000 (a/o Oct 23, 2016)
Outstanding Shares: 34,341,667 (a/o Oct 23, 2016)

As a publicly traded company, AngioSoma, Inc. provides news on its operations through press release distributors like Business Wire, but it provides the same news here in an expanded format with links to all of the initial released locations and expanded images. This conforms to Regulation FD disclosure requirements.

Products in Pipeline

Liprostin

Liprostin™, AngioSoma, Inc.’s flagship product in its product pipeline, is a Peripheral Artery Disease (‘PAD‘) therapy using FDA approved Alprostadil™ (a prostaglandin, referred to as PGE-1) packaged inside a proprietary… Read More →

Transdermal PGE-1 Patch

In September 2016, AngioSoma, Inc. with its Chairman Emeritus David P. ‘Doc‘ Summers PhD filed 2 provisional U.S. Patents and 2 non-provisional U.S. Patents (announced October 11, 2016 in a press release entitled ‘AngioSoma, Inc. Files 3… Read More →

OmniCath

SOAN is filing new patents currently which will, in conjunction with the original base patent, create the OmniCath® II. AngioSoma Research, Inc., a wholly owned Texas subsidiary, own patents associated with the OmniCath® I Read More →

Nutraceuticals

These products have previously generated over ten million dollars ($10,000,000) in sales, through various sales outlets including GNC, while these products were owned and marketed by Endovasc, Inc. in 2005 and 2006: Read More →

Team AngioSoma

AngioSoma, Inc.’s team of professionals underscores the talent that has gone into our pipeline of products as well as the ability to bring those products to value for our shareholders.

Placeholder

Alexanderia Blankenship

CEO


Ms. Blakenship has overseen the acquisition of intellectual property consisting of multiple patents from a private corporation.


Placeholder

David Summers, Ph.D.

Chairman Emeritus


‘Doc’ Summers is our Chairman Emeritus and provides over 35 years of research and development of the products within our product pipeline.


Placeholder

A, Tomas Garcia. III, MD.

Scientific Board of Advisors


Dr. Garcia is a practicing physician in the field of cardiology for the past 35 years and the immediate past president of the Texas Medical Association.


Placeholder

Dr. Jackie R. See, M.D.

Scientific Board of Advisors


Dr. See is a cardiologist and the principal inventor and author of the patent corporate of microsphere technology “PGE1-EDT”.


Placeholder

Robert L. Sonfield

Corporate Counsel


With over 55 years of practice of law, Robert Leon Sonfield, Jr. esq is one of the founders of AngioSoma, Inc. as well as its corporate counsel.

Our Core Values For Stockholders

AngioSoma Inc.
Ticker: SOAN
Status: Fully Reporting
SEC Reporting: Current
Latest Filing: 10Q
Authorized Shares: 480,000,000 (a/o Oct 23, 2016)
Outstanding Shares: 34,341,667 (a/o Oct 23, 2016)

Business Description

AngioSoma, Inc., a Nevada corporation, is a clinical stage biotechnology company focused on improving the effectiveness of current standard-of-care treatments, especially related to endovascular interventions in the treatment of peripheral artery disease (PAD). The Company is developing its lead product, a drug candidate called LiprostinTM for the treatment of peripheral artery disease, or PAD, which has completed FDA Phase I and three Phase II clinical trials. We are in discussions with several contract research organizations for completion of our FDA protocol for Phase III and submission of our new drug application for marketing in the US and its territories.

AngioSoma news releases and the information provided on this website contain forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements that include the words “believes,” “expects,” “anticipate” or similar expressions. Such forward-looking statements involve known and unknown risks, and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone’s past success is no guarantee of future success. This news release speaks as of the date first set forth above and the company assumes no responsibility to update the information included herein for events occurring after the date hereof.

OUR ASSETS

AngioSoma, Inc. has a robust product pipeline, with patents, provisional patents, expired patents with corporate intellectual property / knowledge, registered trademarks, and many more to come. Here are the most important current corporate assets that contribute to our shareholder value.

LIPROSTIN™ PHARMACEUTICAL

Liprostin™ is a treatment for PAD that has completed FDA Phase I and three Phase II clinical trials. We are in discussions with contract research organizations (“CRO”) for completion of our U.S. Food and Drug Administration (“FDA”) protocol for Phase III and submission of our new drug application for marketing in the US and its territories.
TRANSDERMAL PGE-1 PATCH

The Transdermal PGE-1 Patch for the delivery of PGE-1 and / or Liprostin™ through the skin for the treatment of cardiovascular diseases is part of a group of 2 Provisional US Patents and 2 Non-Provisional US Patents filed in September 2016 by AngioSoma, Inc.
OMNICATH I & OMNICATH II

The OmniCath I is an atherectomy catheter that helps plaque removal by drilling, pulverizing and shaving it. The OmniCath I is protected by US Patent 5,728,129, and AngioSoma, Inc. is filing new patents currently which will, in conjunction with the original base patent, create the OmniCath™ II.
SOMA NUTRICEUTICALS, INC.

Soma Nutriceuticals, Inc. provides patented nutraceutical products that increase muscle mass as well as non-patented nutraceutical products with proprietary formulas for aiding sleep, erections, stamina, and other uses.